The Renin-Angiotensin system and right ventricular structure and function: The MESA-Right ventricle study

Pulmonary Circulation

Volumn 2, Issue 3, 2012, Pages 379-386

  Ventetuolo, Corey E ^a   Lima, Joao A C ^b,c   Barr, R Graham ^d,e   Bristow, Michael R ^f   Bagiella, Emilia ^g   Chahal, Harjit ^b   Kizer, Jorge R ^h   Lederer, David J ^d   Bluemke, David A ⁱ   Kawut, Steven M ^j  

^a BROWN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d University of Colorado Denver ^*  (United States)

^e Department of Medicine   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitor; Epidemiology; Renin angiotensin system; Right ventricle

Indexed keywords

EID: 85009832691     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.101657     Document Type: Article

References (52)

1. Orfanos SE, Langleben D, Khoury J, Schlesinger RD, Dragatakis L, Roussos C, et al. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in humans. Circulation 1999;99:1593-9.
2. Morrell NW, Morris KG, Stenmark KR. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol 1995;269:H1186-94.
3. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000;87:E1-9.
4. Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, et al. Angiotensinconverting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010;122:717-28.
5. Yamazato Y, Ferreira AJ, Hong KH, Sriramula S, Francis J, Yamazato M, et al. Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer. Hypertension 2009;54:365-71.
6. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Diez-Freire C, Dooies A, et al. The ace2/ang-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2010:182:1065-72.
7. Okada M, Harada T, Kikuzuki R, Yamawaki H, Hara Y. Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats. J Pharmacol Sci 2009;111:193-200.
8. Schuster DP, Crouch EC, Parks WC, Johnson T, Botney MD. Angiotensin converting enzyme expression in primary pulmonary hypertension. Am J Respir Crit Care Med 1996;154:1087-91.
9. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, et al. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: Evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation 2003;108:1707-12.
10. Leier C, Bambach D, Nelson S, Hermiller J, Huss P, Magorien R, et al. Captopril in primary pulmonary hypertension. Circulation 1983;67: 155-61.
11. Rich S, Martinez J, Lam W, Rosen KM. Captopril as treatment for patients with pulmonary hypertension. Problem of variability in assessing chronic drug treatment. Br Heart J 1982;48:272-7.
12. Zielinski J, Hawrylkiewicz I, Gorecka D, Gluskowski J, Koscinska M. Captopril effects on pulmonary and systemic hemodynamics in chronic cor pulmonale. Chest 1986;90:562-5.
13. Ventetuolo CE, Bagiella E, Barr RG, Bluemke DA, Bristow MR, Chahal H, et al. Angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use and right ventricular structure and function: The MESA-Right Ventricle Study. Am J Respir Crit Care Med 2010;181:A4854.
14. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-Ethnic Study of Atherosclerosis: Objectives and design. Am J Epidemiol 2002;156:871-81.
15. Natori S, Lai S, Finn JP, Gomes AS, Hundley WG, Jerosch-Herold M, et al. Cardiovascular function in Multi-Ethnic Study of Atherosclerosis: Normal values by age, sex, and ethnicity. Am J Roentgenol 2006;186:S357-65.
16. Chahal H, Johnson W, Tandri H, Jain A, Hundley W, Barr R, et al. Relation of cardiovascular risk factors to right ventricular structure and function as determined by magnetic resonance imaging (results from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol 2010;106:110-6.
17. Vogel-Claussen J, Finn JP, Gomes AS, Hundley GW, Jerosch-Herold M, Pearson G, et al. Left ventricular papillary muscle mass: Relationship to left ventricular mass and volumes by magnetic resonance imaging. J Comp Assist Tomogr 2006;30:426-32.
18. Psaty B, Lee M, Savage PJ, Rutan GH, German PS, Lyles M. Assessing the use of medication in the elderly: methods and initial experience in the Cardiovascular Health Study: The Cardiovascular Health Study Collaborative Research Group. J Clin Epidemiol 1992;45:683-92.
19. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, et al. Percentemphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010;362:217-27.
20. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. New Engl J Med 2001;344:1351-7.
21. Kaparianos A, Argyropoulou E. Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: Their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Curr Med Chem 2011;18:3506-15.
22. Ikram H, Maslowski AH, Nicholls MG, Espiner EA, Hull FT. Haemodynamic and hormonal effects of captopril in primary pulmonary hypertension. Br Heart J 1982;48:541-5.
23. Boschett i E, Tantucci C, Cocchieri M, Fornari G, Grassi V, Sorbini CA. Acute effects of captopril in hypoxic pulmonary hypertension. Comparison with transient oxygen administration. Respiration 1985;48:296-302.
24. Bertoli L, Lo Cicero S, Busnardo I, Rizzato G, Montanari G. Effects of captopril on hemodynamics and blood gases in chronic obstructive lung disease with pulmonary hypertension. Respiration 1986;49:251-6.
25. Peacock AJ, Matthews A. Transpulmonary angiotensin II formation and pulmonary haemodynamics in stable hypoxic lung disease: The effect of captopril. Respir Med 1992;86:21-6.
26. Lester SJ, McElhinney DB, Viloria E, Reddy GP, Ryan E, Tworetzky W, et al. Effects of losartan in patients with a systemically functioning morphologic right ventricle after atrial repair of transposition of the great arteries. Am J Cardiol 2001;88:1314-6.
27. Therrien J, Provost Y, Harrison J, Connelly M, Kaemmerer H, Webb GD. Effect of angiotensin receptor blockade on systemic right ventricular function and size: A small, randomized, placebo-controlled study. Int J Cardiol 2008;129:187-92.
28. Hechter SJ, Fredriksen PM, Liu P, Veldtman G, Merchant N, Freeman M, et al. Angiotensin-converting enzyme inhibitors in adults after the Mustard procedure. Am J Cardiol 2001;87:660-3.
29. Cowan B, Young A, Anderson C, Doughty R, Kritt ayaphong R, Lonn E, et al. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]). Am J Cardiol 2009;104:1484-9.
30. Roeleveld RJ, Vonk-Noordegraaf A, Marcus JT, Bronzwaer JG, Marques KM, Postmus PE, et al. Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension. Chest 2004;125:572-9.
31. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. The Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
32. van Wolferen SA, van de Veerdonk MC, Mauritz GJ, Jacobs W, Marcus JT, Marques KM, et al. Clinically significant change in stroke volume in pulmonary hypertension. Chest 2011;139:1003-9.
33. Gardin JM, Wagenknecht LE, Anton-Culver H, Flack J, Gidding S, Kurosaki T, et al. Relationship of cardiovascular risk factors to echocardiographic left ventricular mass in healthy young black and white adult men and women: The CARDIA Study. Circulation 1995;92:380-7.
34. Lorber R, Gidding SS, Daviglus ML, Colangelo LA, Liu K, Gardin JM. Influence of systolic blood pressure and body mass index on left ventricular structure in healthy African-American and white young adults: The CARDIA study. J Am Coll Cardiol 2003;41:955-60.
35. Kizer JR, Arnett DK, Bella JN, Paranicas M, Rao DC, Province MA, et al. Differences in left ventricular structure between black and white hypertensive adults. Hypertension 2004;43:1182-8.
36. Rodriguez CJ, Diez-Roux AV, Moran A, Jin Z, Kronmal RA, Lima J, et al. Left ventricular mass and ventricular remodeling among hispanic subgroups compared with non-hispanic blacks and whites: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2010;55:234-42.
37. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial. Circulation 2003;108:684-90.
38. Gerdts E, Cramariuc D, de Simone G, Wachtell K, Dahlöf B, Devereux RB. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). Eur J Echocardiogr 2008;9:809-15.
39. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. New Engl J Med 1999;340:609-16.
40. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials. J Card Fail 1999;5:178-87.
41. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. New Engl J Med 2004;351:2049-57.
42. Gabler NB, French B, Strom BL, Liu Z, Palevsky HI, Taichman DB, et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 2012;141:20-6.
43. Urashima T, Zhao M, Wagner R, Fajardo G, Farahani S, Quertermous T, et al. Molecular and physiological characterization of RV remodeling in a murine model of pulmonary stenosis. Am J Physiol Heart Circ Physiol 2008;295:H1351-68.
44. Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA, et al. Angiotensin-converting enzyme in the human heart: Effect of the deletion/insertion polymorphism. Circulation 1995; 92:1387-8.
45. Pinto YM, van Gilst WH, Herre Kingma J, Schunkerth H. Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. J Am Coll Cardiol 1995;25:1622-6.
46. Andersson B, Sylven C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 1996;28:162-7.
47. Abraham WT, Raynolds MV, Gottschall B, Badesch DB, Wynne KM, Groves BM, et al. Importance of angiotensin-converting enzyme in pulmonary hypertension. Cardiology 1995;86:9-15.
48. Abraham WT, Raynolds MV, Badesch DB, Wynne KM, Groves BM, Roden RL, et al. Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics. J Renin Angiotensin Aldosterone Syst 2003;4:27-30.
49. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) Study. Circulation 2005;111:3374-83.
50. Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation 1993;87:755-63.
51. Lønnebakken MT, Gerdts E, Boman K, Wachtell K, Dahlöf B, Devereux RB. In-treatment stroke volume predicts cardiovascular risk in hypertension. J Hypertens 2011;29:1508-14.
52. Aaron C, Tandri H, Barr R, Johnson C, Bagiella E, Chahal H, et al. Physical activity and right ventricular structure and function: The MESA-Right Ventricle Study. Am J Respir Crit Care Med 2011;183:396-404.